To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Exclusion Criteria

• •1. Serious risk of suicide in the opinion of the investigator.
• •2. History of substance or alcohol use disorder (excluding nicotine or caffeine) within 12 months prior to signing the informed consent form (ICF).
• •3. Receipt of severe acute respiratory syndrome coronavirus 2(SARS-CoV2) vaccine or booster within 7 days of planned dosing.
• •4. Have recently been diagnosed with symptomatic Coronavirus Disease 2019 (COVID-19) or test positive for COVID-19 within 30 days prior to signing the ICF.
• •5. Positive drug screen including tetrahydrocannabinol (THC).
• •6. Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
• •7. Positive drug screen including THC (except with a vail prescription other than medical marijuana).
• •8. Participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list.
• •9. Participants who require dialysis.
• •10. Participant with nephrotic syndrome.
• •11. Abnormal hemoglobin.
• •12. Abnormal blood pressure measurement or heart rate at Screening or Check-in.